Watanabe T - Search Results

1

Effect of IFN-beta on human glioma cell lines with temozolomide resistance.

Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E. Yoshino A, et al. Among authors: watanabe t. Int J Oncol. 2009 Jul;35(1):139-48. doi: 10.3892/ijo_00000322. Int J Oncol. 2009. PMID: 19513561

2

Growth control of C6 glioma in vivo by nerve growth factor.

Kimura S, Yoshino A, Katayama Y, Watanabe T, Fukushima T. Kimura S, et al. Among authors: watanabe t. J Neurooncol. 2002 Sep;59(3):199-205. doi: 10.1023/a:1019919019497. J Neurooncol. 2002. PMID: 12241115

3

Treatment of low-grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy.

Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, Fukushima T. Watanabe T, et al. J Neurooncol. 2003 Jan;61(2):171-6. doi: 10.1023/a:1022120325619. J Neurooncol. 2003. PMID: 12622456

4

O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.

Watanabe T, Katayama Y, Komine C, Yoshino A, Ogino A, Ohta T, Fukushima T. Watanabe T, et al. Int J Cancer. 2005 Feb 10;113(4):581-7. doi: 10.1002/ijc.20625. Int J Cancer. 2005. PMID: 15455376

5

Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas.

Watanabe T, Katayama Y, Yoshino A, Fukaya C, Yamamoto T. Watanabe T, et al. J Neurooncol. 2005 Mar;72(1):57-62. doi: 10.1007/s11060-004-2160-x. J Neurooncol. 2005. PMID: 15803376 Clinical Trial.

6

Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA.

Yoshino A, Katayama Y, Yokoyama T, Watanabe T, Ogino A, Ota T, Komine C, Fukushima T, Kusama K. Yoshino A, et al. Among authors: watanabe t. J Neurooncol. 2005 Sep;74(3):249-60. doi: 10.1007/s11060-004-7316-1. J Neurooncol. 2005. PMID: 16187022

7

Preliminary individualized chemotherapy for malignant astrocytomas based on O6-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis.

Watanabe T, Katayama Y, Ogino A, Ohta T, Yoshino A, Fukushima T. Watanabe T, et al. Neurol Med Chir (Tokyo). 2006 Aug;46(8):387-93; discussion 393-4. doi: 10.2176/nmc.46.387. Neurol Med Chir (Tokyo). 2006. PMID: 16936459 Free article.

8

Aberrant promoter hypermethylation profile of cell cycle regulatory genes in malignant astrocytomas.

Ohta T, Watanabe T, Katayama Y, Yoshino A, Yachi K, Ogino A, Komine C, Fukushima T. Ohta T, et al. Among authors: watanabe t. Oncol Rep. 2006 Nov;16(5):957-63. Oncol Rep. 2006. PMID: 17016577

9

Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.

Yoshino A, Katayama Y, Ogino A, Watanabe T, Yachi K, Ohta T, Komine C, Yokoyama T, Fukushima T. Yoshino A, et al. Among authors: watanabe t. J Neurooncol. 2007 Jun;83(2):153-62. doi: 10.1007/s11060-006-9316-9. Epub 2007 Jan 11. J Neurooncol. 2007. PMID: 17216555

10

Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.

Yachi K, Watanabe T, Ohta T, Fukushima T, Yoshino A, Ogino A, Katayama Y, Nagase H. Yachi K, et al. Among authors: watanabe t. Int J Oncol. 2008 Sep;33(3):469-75. Int J Oncol. 2008. PMID: 18695875

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,226 results

Search Page

Filters